

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:	:	Chapter 11
PURDUE PHARMA L.P., <i>et al.</i> ,	:	Case No. 19-23649 (RDD)
Debtors. ¹	:	(Jointly Administered)

**TWELFTH MONTHLY FEE STATEMENT OF KPMG LLP FOR COMPENSATION
FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS TAX CONSULTANT FOR THE DEBTORS
AND THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS
FOR THE PERIOD FROM DECEMBER 1, 2020 THROUGH DECEMBER 31, 2020**

Name of Applicant:	KPMG LLP
Authorized to Provide Professional Services to:	The Debtors and the Official Committee of Unsecured Creditors
Date of Retention:	February 24, 2020, <i>nunc pro tunc</i> to December 23, 2019
Period for Which Compensation and Reimbursement is Sought:	December 1, 2020 through December 31, 2020
Amount of Compensation Sought as Actual, Reasonable, and Necessary:	\$ 40,898.80
Less 20% Holdback:	\$ (8,179.76)
Amount of Expense Reimbursement Sought as Actual, Reasonable, and Necessary:	\$ 0.00
Total Fees and Expenses Due:	\$ 32,719.04

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Dated: February 4, 2021

/s/ Howard Steinberg

Howard Steinberg

Partner, KPMG LLP

1350 Avenue of the Americas

New York, New York 10019

(212) 872-6562

EXHIBIT A

Purdue Pharma L.P.

Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional
December 1, 2020 through December 31, 2020

Professional Person	Position & Department	Country of Origin	Total Billed Hours	Hourly Billing Rate	Total Compensation
Ashley Armfield	Senior Associate - M&A Tax	US	8.0	\$ 534	\$ 4,272.00
Bela Unell	Managing Director - Washington National Tax	US	1.1	\$ 905	\$ 995.50
Casey Nunez	Managing Director - M&A Tax	US	5.0	\$ 794	\$ 3,970.00
Devon Rowles	Associate - M&A Tax	US	5.5	\$ 350	\$ 1,925.00
Douglas Holland	Principal - Washington National Tax	US	1.1	\$ 985	\$ 1,083.50
Frankie Angeleri	Senior Associate - Economic & Valuation Services	US	5.0	\$ 533	\$ 2,665.00
Howard Steinberg	Partner - M&A Tax	US	3.9	\$ 856	\$ 3,338.40
Isaac Hirsch	Managing Director - Int'l Tax	US	6.2	\$ 819	\$ 5,077.80
Jess Commisso	Associate - M&A Tax	US	28.9	\$ 350	\$ 10,115.00
Kieran Taylor	Senior Manager - Tax	US	3.5	\$ 744	\$ 2,604.00
Mark Hoffenberg	Principal - Washington National Tax	US	1.1	\$ 980	\$ 1,078.00
Molly Minnear	Principal - Economic & Valuation Services	US	0.3	\$ 868	\$ 260.40
Monica Plangman	Director - Bankruptcy	US	1.2	\$ 279	\$ 334.80
Pete DiMatteo	Manager - Int'l Tax	US	1.1	\$ 650	\$ 715.00
Wendy Shaffer	Manager - Bankruptcy	US	12.2	\$ 202	\$ 2,464.40
Subtotal of Hours and Discounted Fees			84.1		\$ 40,898.80
Total Discounted Fees					\$ 40,898.80
Out of Pocket Expenses					\$ -
Total Fees and Out of Pocket Expenses					\$ 40,898.80
Less Holdback Adjustment (20%)					\$ (8,179.76)
Net Requested Fees & Out of Pocket Expenses					\$ 32,719.04
Blended Hourly Rate				\$ 486.31	

EXHIBIT B

Purdue Pharma L.P.

Case No. 19-23649

Summary of Hours and Discounted Fees Incurred by Category
December 1, 2020 through December 31, 2020

Category	Exhibit	Total Billed Hours	Total Fees Requested
Bankruptcy Tax Consulting Services	C1	68.2	\$ 36,114.60
Non -Working Travel Time	C2	0.0	\$ -
Retention Services	C3	0.0	\$ -
Fee Application Preparation Services	C4	15.9	\$ 4,784.20
Total		84.1	\$ 40,898.80

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	12/01/20	Review of illustrative tax adjustment calculation deliverable, including key modeling assumptions / simplifications, prior to external call.	0.4	\$ 534	\$ 213.60
Ashley Armfield	12/01/20	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 534	\$ 587.40
Bela Unell	12/01/20	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 905	\$ 995.50
Casey Nunez	12/01/20	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 794	\$ 873.40

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
Howard Steinberg	12/01/21	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 856	\$ 941.60
Douglas Holland	12/01/20	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 985	\$ 1,083.50
Isaac Hirsch	12/01/20	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 819	\$ 900.90
Jess Commisso	12/01/20	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 350	\$ 385.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services
December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
Mark Hoffenberg	12/01/20	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 980	\$ 1,078.00
Pete DiMatteo	12/01/20	Call with M. Hoffenberg (Washington National Tax – Lead tax partner – Corporate tax), H. Steinberg (M&A tax – core US team member – Lead tax partner), D. Holland (Washington National Tax – International tax specialist), B. Unell (Washington National Tax – Managing Director specialist in bankruptcy restructurings), I. Hirsch (International tax – core US team member), C. Nunez (M&A tax – core US team member), P. DiMatteo (International tax – core US team member), A. Armfield (M&A tax – core US team member), and J. Commisso (M&A tax – core US team member) (all KPMG) to discuss effects of a tax modeling on settlement and overall next steps.	1.1	\$ 650	\$ 715.00
Casey Nunez	12/01/20	(1.4) Performed M&A Tax Managing Director review of certain tax modeling example schedules for illustrating impact of an adjustment to be provided to Akin and Davis Polk	1.4	\$ 794	\$ 1,111.60
Ashley Armfield	12/01/20	1.6 Reviewed Alix Partners' cash distribution memo pursuant to updating cash tax model for relevant assumptions.	1.6	\$ 534	\$ 854.40
Isaac Hirsch	12/01/20	(1.8) Prepare for external call to discuss effects of a certain adjustment on the settlement as well as overall next steps by reviewing latest version of Purdue cash tax model along with related assumptions.	1.8	\$ 819	\$ 1,474.20
Kieran Taylor	12/02/20	Call with F. Angeleri (KPMG) to discuss further findings related to Purdue structure from a tax modeling perspective.	0.2	\$ 744	\$ 148.80
Frankie Angeleri	12/02/20	Call with K. Taylor (KPMG) to discuss further findings related to Purdue structure from a tax modeling perspective.	0.2	\$ 533	\$ 106.60
Jess Commisso	12/02/20	0.6 Review of certain tax modeling and tax law pursuant to application of a certain adjustment in the cash tax model.	0.6	\$ 350	\$ 210.00
Isaac Hirsch	12/02/20	Communication via email with Akin and Davis Polk regarding updates to cash tax modeling for certain tax adjustments and the impact on net proceeds	1.2	\$ 819	\$ 982.80
Frankie Angeleri	12/02/20	3.8 Adding additional information to the transactions summary / flow chart based on previous discussion with K. Taylor (KPMG).	3.8	\$ 533	\$ 2,025.40

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
Frankie Angeleri	12/02/20	0.2 Updated the tax related summary to include source information.	0.2	\$ 533	\$ 106.60
Ashley Armfield	12/03/20	0.4 Planning of tax strategy for updating cash tax model for sensitivity analysis based on external calls.	0.4	\$ 534	\$ 213.60
Howard Steinberg	12/03/20	Perform Partner review of the illustrative tax adjustment model, including key modeling assumptions, prior to issuing client deliverable.	1.4	\$ 856	\$ 1,198.40
Kieran Taylor	12/03/20	Performed Senior Manager review of transaction diagram flow.	1.8	\$ 744	\$ 1,339.20
Jess Commisso	12/04/20	0.8 Performed brainstorming related to best approach to update the cash tax model pursuant to incorporation of certain tax adjustments.	0.8	\$ 350	\$ 280.00
Ashley Armfield	12/04/20	1.1 Discussion with A. Armfield, D. Rowles, and J. Commisso (all KPMG) on cash tax model updates pursuant to implementation of a certain tax adjustment.	1.1	\$ 534	\$ 587.40
Devon Rowles	12/04/20	1.1 Discussion with A. Armfield, D. Rowles, and J. Commisso (all KPMG) on cash tax model updates pursuant to implementation of a certain tax adjustment.	1.1	\$ 350	\$ 385.00
Jess Commisso	12/04/20	1.1 Discussion with A. Armfield, D. Rowles, and J. Commisso (all KPMG) on cash tax model updates pursuant to implementation of a certain tax adjustment.	1.1	\$ 350	\$ 385.00
Ashley Armfield	12/07/20	0.4 Drafting email to J. Commisso and D. Rowles (both KPMG) regarding cash tax model updates, specifically to include certain tax adjustments.	0.4	\$ 534	\$ 213.60
Isaac Hirsch	12/07/20	(0.6) Performed managing director review of updates to cash tax model, as of 12/7/2020, with focus on proposed tax adjustment	0.6	\$ 819	\$ 491.40
Ashley Armfield	12/07/20	0.8 Discussion with I. Hirsch, A. Armfield, D. Rowles, and J. Commisso (all KPMG) regarding the implementation of a certain tax adjustment into the cash tax model.	0.8	\$ 534	\$ 427.20
Isaac Hirsch	12/07/20	0.8 Discussion with I. Hirsch, A. Armfield, D. Rowles, and J. Commisso (all KPMG) regarding the implementation of a certain tax adjustment into the cash tax model.	0.8	\$ 819	\$ 655.20
Jess Commisso	12/07/20	0.8 Discussion with I. Hirsch, A. Armfield, D. Rowles, and J. Commisso (all KPMG) regarding the implementation of a certain tax adjustment into the cash tax model.	0.8	\$ 350	\$ 280.00
Kieran Taylor	12/07/20	Senior Manager review of the intercompany flow chart prepared by F. Angeleri (KPMG) to consider the potential tax adjustments available.	1.2	\$ 744	\$ 892.80
Jess Commisso	12/07/20	1.8 Continue, from same day, to update the Purdue cash tax model pursuant to incorporating a certain tax adjustment.	1.8	\$ 350	\$ 630.00
Jess Commisso	12/07/20	3.9 Updates to the Purdue cash tax model, as of 12/7/2020, pursuant to incorporating a certain tax adjustment.	3.9	\$ 350	\$ 1,365.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
Frankie Angeleri	12/08/20	0.2 Drafted email of certain transactions to M. Minnear and K. Taylor (both KPMG); 0.3 Drafted email regarding certain transactions and overall findings regarding potential for certain tax adjustments to the KPMG M&A project team.	0.5	\$ 533	\$ 266.50
Frankie Angeleri	12/08/20	Meeting with M. Minnear, K. Taylor, and F. Angeleri (all KPMG) to discuss certain transactions and potential tax adjustments.	0.3	\$ 533	\$ 159.90
Kieran Taylor	12/08/20	Meeting with M. Minnear, K. Taylor, and F. Angeleri (all KPMG) to discuss certain transactions and potential tax adjustments.	0.3	\$ 744	\$ 223.20
Molly Minnear	12/08/20	Meeting with M. Minnear, K. Taylor, and F. Angeleri (all KPMG) to discuss certain transactions and potential tax adjustments.	0.3	\$ 868	\$ 260.40
Jess Commisso	12/08/20	Updates to the cash tax model, as of 12/8/2020, pursuant to incorporating a certain tax adjustment.	3.0	\$ 350	\$ 1,050.00
Isaac Hirsch	12/10/20	Performed managing director review of updates to cash tax model for potential tax adjustment	0.3	\$ 819	\$ 245.70
Jess Commisso	12/14/20	1.1 Continue, same day, to update the Purdue cash tax model pursuant to incorporating certain tax adjustments (including waterfall impact throughout disposition entities and shareholders).	1.3	\$ 350	\$ 455.00
Ashley Armfield	12/14/20	1.1 Call with A. Armfield, J. Commisso, and D. Rowles (all KPMG) regarding updates to the Purdue cash tax model pursuant to incorporation of certain tax adjustments.	1.1	\$ 534	\$ 587.40
Devon Rowles	12/14/20	1.1 Call with A. Armfield, J. Commisso, and D. Rowles (all KPMG) regarding updates to the Purdue cash tax model pursuant to incorporation of certain tax adjustments.	1.1	\$ 350	\$ 385.00
Jess Commisso	12/14/20	1.1 Call with A. Armfield, J. Commisso, and D. Rowles (all KPMG) regarding updates to the Purdue cash tax model pursuant to incorporation of certain tax adjustments.	1.1	\$ 350	\$ 385.00
Jess Commisso	12/14/20	Updates to the cash tax model, as of 12/14/20, pursuant to incorporating certain tax adjustments and the impact on cash flows of shareholders in structure.	3.2	\$ 350	\$ 1,120.00
Ashley Armfield	12/15/20	1.1 Call with A. Armfield, D. Rowles, and J. Commisso (all KPMG) to discuss the integration of tax adjustments into the cash tax model as well as the drafting of key modeling assumptions.	1.1	\$ 534	\$ 587.40
Devon Rowles	12/15/20	1.1 Call with A. Armfield, D. Rowles, and J. Commisso (all KPMG) to discuss the integration of tax adjustments into the cash tax model as well as the drafting of key modeling assumptions.	1.1	\$ 350	\$ 385.00
Jess Commisso	12/15/20	1.1 Call with A. Armfield, D. Rowles, and J. Commisso (all KPMG) to discuss the integration of tax adjustments into the cash tax model as well as the drafting of key modeling assumptions.	1.1	\$ 350	\$ 385.00
Devon Rowles	12/15/20	1.3 Updates to the Purdue cash tax model to incorporate the certain tax modeling.	1.3	\$ 350	\$ 455.00
Jess Commisso	12/15/20	2.7 Continued (same day) to update the Purdue cash tax model pursuant to incorporating a certain tax adjustment.	2.0	\$ 350	\$ 700.00

EXHIBIT C1

Purdue Pharma L.P.

Case No. 19-23649

Bankruptcy Tax Consulting Services

December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	12/15/20	3.2 Updates to the Purdue cash tax model pursuant to incorporating a certain tax adjustments, including local country tax treatment (10 jurisdictions).	3.9	\$ 350	\$ 1,365.00
Devon Rowles	12/16/20	Updates to the Purdue cash tax model, as of 12/16/20, pursuant to integrating certain tax adjustments.	0.9	\$ 350	\$ 315.00
Jess Commisso	12/16/20	Updates to the cash tax model, as of 12/16/20, pursuant to incorporating a certain tax adjustments in relevant local jurisdictions.	3.2	\$ 350	\$ 1,120.00
Isaac Hirsch	12/21/20	Drafted email to Akin and Davis Polk regarding response to Houlihan Lokey related to correspondence with certain advisors.	0.4	\$ 819	\$ 327.60
Howard Steinberg	12/21/20	Performed Partner review of cash tax model, specifically regarding assumptions for potential tax adjustments.	1.4	\$ 856	\$ 1,198.40
Total Bankruptcy Tax Consulting Services			<u>68.2</u>		<u>\$ 36,114.60</u>

EXHIBIT C2

Purdue Pharma L.P.

Case No. 19-23649

Non -Working Travel Time

December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
		<i>no fees billed for these services in current month</i>			
		Total Non-Working Travel Time			<u><u>\$ -</u></u>

EXHIBIT C3

Purdue Pharma L.P.

Case No. 19-23649

Retention Services

December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
<i>no fees billed for these services in current month</i>					
Total Retention Services			<u><u>0.0</u></u>		<u><u>\$ -</u></u>

EXHIBIT C4

Purdue Pharma L.P.

Case No. 19-23649

Fee Application Preparation Services
December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	12/01/20	0.3 Updates to Purdue 10th monthly fee statement per direction from Davis Polk and 0.1 finalization (PDF) of same and 0.1 drafted email to send updated version to Davis Polk for filing.	0.5	\$ 202	\$ 101.00
Wendy Shaffer	12/02/20	0.1 Drafted email to C. Nunez (KPMG) with copy of filed version of Purdue Pharma 10th monthly and related objection deadline	0.1	\$ 202	\$ 20.20
Wendy Shaffer	12/03/20	0.1 Begin to prepare cover sheet for Purdue Pharma 11th monthly fee statement and 0.2 updated exhibit C1 of Purdue Pharma 11th monthly fee statement to include data received from KPMG foreign member firms as of 12/3/2020	0.3	\$ 202	\$ 60.60
Wendy Shaffer	12/03/20	0.4 Begin to create exhibits for Purdue Pharma 11th monthly fee statement.	0.4	\$ 202	\$ 80.80
Wendy Shaffer	12/06/20	0.2 Prepared Purdue Pharma 10th monthly fee statement in Excel and 0.1 send to M. Plangman (KPMG) via email for review/approval. 0.1 Drafted email to T. Nobis (Purdue Fee Examiner) to provide copy of KPMG 10th monthly fee statement in excel as requested.	0.4	\$ 202	\$ 80.80
Wendy Shaffer	12/08/20	1.0 Updates to exhibit C1 of Purdue Pharma 11th monthly fee statement to include data received from professionals as of 12/08/2020	1.0	\$ 202	\$ 202.00
Wendy Shaffer	12/09/20	0.3 Call with M. Plangman (KPMG) regarding go forward to address Purdue fee examiner report.	0.3	\$ 202	\$ 60.60
Monica Plangman	12/10/20	Call with S. Carlin, M. Plangman, W. Shaffer, J. Roberts and C. Nunez (KPMG) to discuss Fee Examiner report and go-forward.	0.4	\$ 279	\$ 111.60
Casey Nunez	12/10/20	Call with S. Carlin, M. Plangman, W. Shaffer, J. Roberts and C. Nunez (KPMG) to discuss Fee Examiner report and go-forward.	0.4	\$ 794	\$ 317.60
Wendy Shaffer	12/10/20	Call with S. Carlin, M. Plangman, W. Shaffer, J. Roberts and C. Nunez (KPMG) to discuss Fee Examiner report and go-forward.	0.4	\$ 202	\$ 80.80
Wendy Shaffer	12/10/20	1.9 Updates to exhibit C1 of Purdue Pharma 11th monthly fee statement to include data received from professionals as of 12/10/2020	1.9	\$ 202	\$ 383.80
Wendy Shaffer	12/11/20	0.3 Call with D. Klauder (Purdue Fee Examiner) and S. Carlin (KPMG Office of General Counsel) regarding comments related to KPMG 3rd Interim fee application and 0.1 Drafted email to D. Klauder (Bielli & Klauder, LLC) to confirm agreed upon reduction amount related to KPMG interim application.	0.4	\$ 202	\$ 80.80
Wendy Shaffer	12/15/20	0.1 Review/approve Purdue Proposed Order sent by counsel related to 3rd Interim fee application. 3.5 Updates to Purdue 11th monthly fee statement to include data received from professionals as of 12/15/2020;	3.6	\$ 202	\$ 727.20
Wendy Shaffer	12/16/20	0.5 Finalized Purdue Pharma 11th monthly fee statement and 0.1 drafted email to A. Armfield (KPMG) to request revisions of monthly fee application draft with regards to previous comments received from Davis Polk.	0.6	\$ 202	\$ 121.20
Casey Nunez	12/17/20	Performed Managing Director review of Purdue Pharma November monthly fee statement and concurrently drafted review comments to W. Shaffer (KPMG).	1.2	\$ 794	\$ 952.80

EXHIBIT C4

Purdue Pharma L.P.

Case No. 19-23649

Fee Application Preparation Services
December 1, 2020 through December 31, 2020

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	12/18/20	0.6 Updated the Purdue Pharma 11th monthly fee statement to include updates from C. Nunez (KPMG) to address previous comments from Davis Polk and 0.3 finalized same; 0.2 send outstanding questions to team; 0.1 drafted email to send copy of same to M. Plangman (KPMG)	1.2	\$ 202	\$ 242.40
Wendy Shaffer	12/21/20	0.6 Updates to Purdue Pharma 11th monthly fee statement per direction from M. Plangman (KPMG)	0.6	\$ 202	\$ 121.20
Monica Plangman	12/21/20	Performed Director review of November fee statement and concurrently provide comments.	0.8	\$ 279	\$ 223.20
Wendy Shaffer	12/22/20	0.1 Drafted email to H. Steinberg (KPMG) to request review/approval of Purdue Pharma 11th monthly fee statement	0.1	\$ 202	\$ 20.20
Wendy Shaffer	12/22/20	0.1 Finalized Purdue Pharma 11th monthly cover sheet with regards to updated exhibits and 0.1 drafted email to send copy of same to M. Plangman (KPMG) for review/approval.	0.2	\$ 202	\$ 40.40
Wendy Shaffer	12/22/20	0.2 Updates to Purdue Pharma 11th monthly fee statement per direction from C. Nunez (KPMG);	0.2	\$ 202	\$ 40.40
Casey Nunez	12/22/20	Performed Managing Director review of updated Purdue monthly fee statement documents prior to filing.	0.9	\$ 794	\$ 714.60
Total Fee Application Preparation Services			<u>15.9</u>		<u>\$ 4,784.20</u>

EXHIBIT D

Purdue Pharma L.P.

Case No. 19-23649

Summary of Out of Pocket Expenses
December 1, 2020 through December 31, 2020

Category	Amount
Airfare	\$ -
Lodging	\$ -
Meals	\$ -
Ground Transportation	\$ -
Miscellaneous	\$ -
Total	\$ -

EXHIBIT D1

Purdue Pharma L.P.

Case No. 19-23649

Detail of Out of Pocket Expenses
December 1, 2020 through December 31, 2020

Name	Date	Description	Amount
		Air Fare Subtotal	<u>\$ -</u>
		Lodging Subtotal	<u>\$ -</u>
		Meals Subtotal	<u>\$ -</u>
		Total Ground Transportation	<u>\$ -</u>
		Miscellaneous Subtotal	<u>\$ -</u>
		Total Out of Pocket Expenses	<u><u>\$ -</u></u>